Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualizing Therapy with 6-Mercaptopurine and 6-Thioguanine Related to the Thiopurine Methyltransferase Genetic Polymorphism

1 Aug 1996

Abstract excerpt

The formation of intracellular thionucleotides are a prerequisite for mercaptopurine (MP) cytotoxicity, and interindividual variations in the inherited level of thiopurine methyltransferase (TPMT) activity regulate their formation. Measurement of pretreatment TPMT activities can identify the TPMT "deficient" patient and, conversely, the individual with very high enzyme activities. The former are at higher risk of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Biochemical and Molecular Research
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 8857546
DOI: 10.1097/00007691-199608000-00003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualizing Therapy with 6-Mercaptopurine and 6-Thioguanine Related to the Thiopurine Methyltransferase Genetic PolymorphismPMID 8857546Read ↗

Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.Semantic proximity Read ↗

Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.Semantic proximity Read ↗

Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.Semantic proximity Read ↗

Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.Semantic proximity Read ↗

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?Semantic proximity Read ↗

Recent advances in the pharmacogenomics of thiopurine methyltransferase.Semantic proximity Read ↗

Role of TPMT and ITPA variants in mercaptopurine disposition.Semantic proximity Read ↗

Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?Semantic proximity Read ↗

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine TherapySemantic proximity Read ↗

[Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.